Physician profile
Nancy A Scheinost
NPI 1740238450
$5,929.42
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,116 · 2020: $60.77 · 2021: $265 · 2022: $812 · 2023: $3,609 · 2024: $67.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,671 · Education: $5.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,670.61 |
| Education | $5.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $812.84 | 2019-2024 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $803.05 | 2019-2023 | Skyrizi, Rinvoq, Humira |
| Astrazeneca Pharmaceuticals LP | $591.84 | 2022-2023 | Saphnelo |
| Horizon Therapeutics Plc | $449.24 | 2022-2023 | Krystexxa |
| Ucb, INC. | $427.37 | 2019-2023 | Cimzia |
| Lilly USA, LLC | $420.76 | 2019-2023 | Taltz, Olumiant |
| Glaxosmithkline, LLC. | $302.60 | 2023 | Benlysta |
| Janssen Biotech, INC. | $285.96 | 2019-2023 | Simponi Aria, Tremfya |
| Eisai INC. | $245.85 | 2020-2021 | |
| Pfizer INC. | $216.29 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $173.93 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.22 | 2022-2023 | Ofev, Cyltezo |
| Ani Pharmaceuticals, INC. | $141.10 | 2023 | Purified Cortrophin Gel |
| Celgene Corporation | $136.48 | 2019 | |
| Organon LLC | $136.35 | 2023 | Renflexis, Hadlima |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $99.68 | 2022 | |
| Genentech USA, INC. | $67.18 | 2019-2023 | Actemra |
| Actelion Pharmaceuticals US, INC. | $62.81 | 2023 | Opsumit, Uptravi |
| Genzyme Corporation | $46.69 | 2019-2023 | |
| Fresenius Kabi USA, LLC | $46.65 | 2023 | Idacio |
| Sandoz INC. | $45.76 | 2023 | Hyrimoz |
| Aurinia Pharma U.S., INC. | $38.08 | 2022-2023 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $37.30 | 2022-2023 | Acthar |
| Pacira Therapeutics, INC. | $30.03 | 2019 | |
| Mallinckrodt Enterprises LLC | $27.84 | 2019 | |
| Alexion Pharmaceuticals, INC. | $26.12 | 2023 | Ultomiris |
| Sunovion Pharmaceuticals INC. | $16.30 | 2020 | |
| Medexus Pharma, INC. | $15.19 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.53 | 2022 | |
| Novo Nordisk INC | $14.17 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.89 | 2022 | |
| Hikma Pharmaceuticals USA | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Scheinost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.